News
TLPH
0.8858
+0.33%
0.0029
Weekly Report: what happened at TLPH last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at TLPH last week (0708-0712)?
Weekly Report · 07/15 11:58
Weekly Report: what happened at TLPH last week (0701-0705)?
Weekly Report · 07/08 12:00
Weekly Report: what happened at TLPH last week (0624-0628)?
Weekly Report · 07/01 12:01
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Syntec Optics stock is rocketing more than 248% after securing a key patent in Europe. The biggest pre-market stock movers on Wednesday morning are patent news, a new investment, proposed public offerings and more. Check out the top 10 moving stocks this morning.
Investorplace · 06/26 11:41
Talphera Shareholders Affirm Leadership and Financial Strategy
TipRanks · 06/24 22:53
Weekly Report: what happened at TLPH last week (0617-0621)?
Weekly Report · 06/24 12:11
12 Health Care Stocks Moving In Thursday's After-Market Session
Psyence Biomedical stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. Kintara Therapeutics (NASDAQ:KTRA) shares rose by 15.67% during the session. Clover Health Investments and Helius Medical Tech were among the day's gainers.
Benzinga · 06/20 20:31
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday. SMX (Security Matters) stock is rocketing more than 100% alongside heavy pre-market trading. Study data, acquisition updates, a secondary stock offering and more are moving stocks this morning. 10 Top Gainers: SMX stock is soaring over 50% with new study data.
Investorplace · 06/20 11:28
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. Tempest Therapeutics ( NASDAQ:TPST) stock moved upwards by 40.0% during the session. ASLAN Pharma (NASdaq:ASLN) shares increased by 18.51%.
Benzinga · 06/19 20:30
Weekly Report: what happened at TLPH last week (0610-0614)?
Weekly Report · 06/17 11:59
Weekly Report: what happened at TLPH last week (0603-0607)?
Weekly Report · 06/10 12:02
Weekly Report: what happened at TLPH last week (0527-0531)?
Weekly Report · 06/03 12:05
Weekly Report: what happened at TLPH last week (0520-0524)?
Weekly Report · 05/27 12:12
TALPHERA ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/20 21:25
Weekly Report: what happened at TLPH last week (0513-0517)?
Weekly Report · 05/20 12:02
Optimistic Buy Rating for Talphera Despite Phase 3 Trial Enrollment Delay
TipRanks · 05/16 14:45
Talphera Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 05/15 15:01
Analysts Are Bullish on These Healthcare Stocks: Talphera (TLPH), NexGel Inc (NXGL)
TipRanks · 05/15 11:40
TLPH Stock Earnings: Talphera Beats EPS for Q1 2024
Talphera reported earnings per share of -16 cents for the first quarter of 2024. The company did not report any revenue for the quarter. Talphera's earnings were above the analyst estimate for EPS of -22 cents. The stock is down 1.7% today.
Investorplace · 05/15 00:56
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.